Peginterferon alfa-2b  (Synonyms: PegIFN a-2b; Sch 54031; Sylatron; ViraferonPeg)

Peginterferon alfa-2b (PegIFN a-2b; Sch 54031; Sylatron; ViraferonPeg) is an immunomodulator. Peginterferon alfa-2b is a recombinant alfa-2b interferon covalently linked PEG with antiviral activity against HCV. Peginterferon alfa-2b decreases viral DNA in HIV. Peginterferon alfa-2b can be used in research of melanoma and hepatitis C^[1][2].

Peginterferon alfa-2b provides benefits to individuals with cirrhosis due to chronic hepatitis C who already have portal hypertension^[1].
Peginterferon alfa-2b can induce melanogenesis by upregulating melanocortin receptors on melanocytes, thereby causing the adverse reaction of tongue pigmentation^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

31 kDa; PEG 12 kDa

215647-85-1

Liquid

Colorless to light yellow

[Peginterferon alfa-2b]

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  IFNA2 (interferon alpha 2)*b (R46,H57)24-188

• [1]. Bruix J, et al. Maintenance therapy with peginterferon alfa-2b does not prevent hepatocellular carcinoma in cirrhotic patients with chronic hepatitis C. Gastroenterology. 2011 Jun;140(7):1990-9.  [Content Brief]

  [2]. Torres H A, et al. Tongue hyperpigmentation in a Caucasian patient coinfected with HIV and hepatitis C during peginterferon alfa-2b and ribavirin therapy[J]. Official journal of the American College of Gastroenterology| ACG, 2007, 102(6): 1334-1335.  [Content Brief]